



Christoph Jakob Ackermann

Contact

Christoph Jakob Ackermann

Publications (6)

Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribi K, Maranta A, Bastian S, von Moos R, Jörgen M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. *Eur J Cancer* 2024; 200:113600.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563-568.

Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. *Cancer Manag Res* 2018; 10:5537-5544.

Ackermann C, Gueller U, Jochum W, Schmied B, Warschkow R. The prognostic value of signet ring cell histology in stage I/II colon cancer—a population-based, propensity score-matched analysis. *Int J Colorectal Dis* 2018

Guebeli N, Warschkow R, Ackermann C, Schmied B, Cerny T, ess s. Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. *Swiss Med Wkly* 2018; 148:w14583.

Gueller U, Warschkow R, Ackermann C, Schmied B, Cerny T, ess s. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. *Swiss Med Wkly* 2017; 147:w14473.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch